Losada, M. C., Maniar, A., Du, J., Brown, M. L., Young, K., Hilbert, D. W., . . . Chen, L. F. (2020). 1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ). Open Forum Infect Dis.
Citação norma ChicagoLosada, Maria C., et al. "1230. Clinical and Microbiologic Outcomes By Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated With Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)." Open Forum Infect Dis 2020.
Citação norma MLALosada, Maria C., et al. "1230. Clinical and Microbiologic Outcomes By Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated With Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)." Open Forum Infect Dis 2020.